Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2003 Nov 14;11(3):425–443. doi: 10.1046/j.1365-2036.1997.00159.x

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

C M Wilcox 1, K E Mönkemüller 1
PMCID: PMC7159661  PMID: 9218066

Abstract

Although there have been dramatic strides in the therapy of human immunodeficiency virus infection over the last few years, the number of infected people world‐wide is tremendous and, at least in developing countries, continues to expand. Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome. It is important to recognize the clinical spectrum of gastrointestinal diseases, as well as the appropriate and most cost‐effective diagnostic strategies, as therapies for a number of these disorders are both widely available and highly effective. This review summarizes the major gastrointestinal infections which are seen in patients with the acquired immunodeficiency syndrome, and their treatment.

References

  • 1. Connolly GM, Hawkins D, Harcourt‐Webster JN, et al Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. Gut 1989;. 11: 1033–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. May GR, Gill MJ, Church DL, Sutherland LR Gastrointestinal symptoms in ambulatory HIV‐infected patients. Dig Dis Sci 1993;. 11: 1388–94. [DOI] [PubMed] [Google Scholar]
  • 3. Bacellar H, Munoz A, Hoover DR, et al for the Multicenter AIDS cohort study. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3 J Infect Dis 1994;. 11: 1284–7. [DOI] [PubMed] [Google Scholar]
  • 4. Watson A, Samore MH, Wanke CA Diarrhea and quality of life in ambulatory HIV‐infected patients. Dig Dis Sci 1996;. 11: 1794–800. [DOI] [PubMed] [Google Scholar]
  • 5. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993;. 11: 1922–6. [DOI] [PubMed] [Google Scholar]
  • 6. Selik RM, Chu SY, Ward JW Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992 Ann Intern Med 1995;. 11: 933–6. [DOI] [PubMed] [Google Scholar]
  • 7. Weinert M, Grimes RM, Lynch DP Oral manifestations of HIV infection. Ann Intern Med 1996;. 11: 485–96. [DOI] [PubMed] [Google Scholar]
  • 8. Coleman DC, Bennett DE, Sullivan DJ, et al Oral Candida in HIV infection and AIDS: New perspectives/new approaches. Crit Rev Microbiol 1993;. 11: 61–82. [DOI] [PubMed] [Google Scholar]
  • 9. Wilcox CM, Straub RF, Clark WS Prospective evaluation of oropharyngeal findings in human immunodeficiency virus‐infected patients with esophageal ulcer. Am J Gastroenterol 1995;. 11: 1938–41. [PubMed] [Google Scholar]
  • 10. Bonacini M, Young T, Laine L The causes of esophageal symptoms in human immunodeficiency virus infection: A prospective study of 110 patients. Arch Intern Med 1991;. 11: 1567–72. [PubMed] [Google Scholar]
  • 11. Wilcox CM Evaluation of a technique to evaluate the underlying mucosa in patients with AIDS and severe Candida esophagitis. Gastrointest Endosc 1995;. 11: 360–3. [DOI] [PubMed] [Google Scholar]
  • 12. Wilcox CM, Alexander LN, Clark WS, Thompson SE Fluconazole compared with endoscopy for human immunodeficiency virus‐infected patients with esophageal symptoms. Gastroenterology 1996;. 11: 1803–9. [DOI] [PubMed] [Google Scholar]
  • 13. Koletar SL, Russell JA, Fass RJ, Plouffe JF Comparison of oral fluconazole and clotrimazole troches as treatment of oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990;. 11: 2267–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Pons V, Greenspan D, Derbruin M, et al. Therapy for oropharyngeal candidiasis in HIV‐infected patients: A randomized, prospective multicenter study of oral fluconazole vs. clotrimazole troches. J Acquir Immune Defic Syndr 1993;. 11: 1311–5. [PubMed] [Google Scholar]
  • 15. Como JA & Dismukes WE Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;. 11: 263–72. [DOI] [PubMed] [Google Scholar]
  • 16. DeMuria D, Forrest A, Rich J, Scavone JM, Cohen LG, Kazanjian PH Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993;. 11: 2187–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Lim SG, Sawyer AM, Hudson M, Sercombe J, Pounder RE Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993;. 11: 317–21. [DOI] [PubMed] [Google Scholar]
  • 18. DeWit S, Goosens H, Clumeck N Single‐dose vs. 7 days of fluconazole treatment for oral candidiasis in human immunodeficiency virus‐infected patients: a prospective, randomized pilot study. J Infect Dis 1993;. 11: 1332–3. [DOI] [PubMed] [Google Scholar]
  • 19. DeWit SD, Weerts D, Goosens H, Clumeck N Comparison of fluconazole and ketoconazole in oropharyngeal candidiasis in AIDS. Lancet 1989; i: 746–7. [DOI] [PubMed]
  • 20. Hernandez‐Sampelayo T & Multicenter Study Group Fluconazole vs. ketoconazole in the treatment of oropharyngeal candidiasis in HIV‐infected children. Eur J Clin Microbiol Infect Dis 1994;. 11: 340–4. [DOI] [PubMed] [Google Scholar]
  • 21. Laine L, Dretler RH, Conteas CN, et al Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992;. 11: 655–60. [DOI] [PubMed] [Google Scholar]
  • 22. Wilcox CM Time course of clinical response to fluconazole for Candida oesphagitis in AIDS. Aliment Pharmacol Ther 1994;. 11: 347–50. [DOI] [PubMed] [Google Scholar]
  • 23. Smith DE, Midgley J, Allan M, Connolly GM, Gazzad BG Itraconazole vs. ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991;. 11: 1367–71. [DOI] [PubMed] [Google Scholar]
  • 24. Barbaro G & Di Lorenzo G Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of oesophageal candidiasis in AIDS patients: a double‐blind, randomized, controlled clinical study. Ital J Gastroenterol 1995;. 11: 175–80. [PubMed] [Google Scholar]
  • 25. Barbaro G, Barbarini G, Caladeron W, et al. Fluconazole vs. itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996;. 11: 1169–77. [DOI] [PubMed] [Google Scholar]
  • 26. Laine L & Rabeneck LR Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment Pharmacol Ther 1995;. 11: 553–6. [DOI] [PubMed] [Google Scholar]
  • 27. Moskovitz BL, Wilcox CM, Darouiche R, Wu J, Mallegol I Itraconazole oral solution (IS) compared with fluconazole (F) for treatment of esophageal candidiasis. Proceedings of the XI International Conference on AIDS. Mo.B.116, 1996, 17 17.
  • 28. Barbaro G, Barbarina G, Di Lorenzo G Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: A double‐blind, placebo‐controlled study. Endoscopy 1995;. 11: 377–83. [DOI] [PubMed] [Google Scholar]
  • 29. Chavanet PY, Garry I, Charlier N, et al. Trial of glucose vs. fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 1992;. 11: 921–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Joly V, Aubry P, Ndayiragide A, et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or intralipid for the treatment of AIDS‐associated cryptococcal meningitis. Clin Infect Dis 1996;. 11: 556–62. [DOI] [PubMed] [Google Scholar]
  • 31. Hiemenz JW & Walsh TJ Lipid formulations of amphotericin B. Recent progress and future directions. Clin Infect Dis 1996;. 11(Suppl. 2): S133–44. [DOI] [PubMed] [Google Scholar]
  • 32. Dewsnup DH & Stevens DA Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Veter Mycol 1994;. 11: 389–93. [DOI] [PubMed] [Google Scholar]
  • 33. Sandven P, Bjorneklett A, Maeland A, et al. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chemother 1993;. 11: 2443–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Baily GG, Perry FM, Denning DW, Mandal BK Fluconazole‐resistant candidosis in an HIV cohort. AIDS 1994;. 11: 787–92. [DOI] [PubMed] [Google Scholar]
  • 35. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MGL, Denning DW High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994;. 11: 659–68. [DOI] [PubMed] [Google Scholar]
  • 36. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG In vitro activity of itraconazole against fluconazole‐susceptible and ‐resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;. 11: 1530–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Revankar SG, Kirkpatrick WR, McAtee RK, et al Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus‐infected patients. J Infect Dis 1996;. 11: 821–7. [DOI] [PubMed] [Google Scholar]
  • 38. Troillet N, Durussel C, Bille J, Clauser MP, Chave JP Correlation between in vitro susceptibility of Candida albicans and fluconazole‐resistant oropharyngeal candidiasis in HIV‐infected patients. Eur J Clin Microbiol Infect Dis 1993;. 11: 911–5. [DOI] [PubMed] [Google Scholar]
  • 39. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE Risk factors for fluconazole‐resistant candidiasis in human immunodeficiency virus‐infected patients. J Infect Dis 1996;. 11: 219–25. [DOI] [PubMed] [Google Scholar]
  • 40. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993;. 11: 2449–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;. 11: 240–2. [DOI] [PubMed] [Google Scholar]
  • 42. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M Emergence of fluconazole‐resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994;. 11: 2092–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Lacassin F, Damond F, Chochillon C, et al. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: Pharmacological and mycological factors. Antimicrob Agents Chemother 1996;. 11: 1961–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Pfaller MA, Rhine‐Chalber J, Redding SW, et al Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;. 11: 59–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Millon L, Manteaux A, Reboux G, et al. Fluconazole‐resistant recurrent oral candidiasis in human immunodeficiency virus‐positive patients: Persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994;. 11: 1115–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Chavenet P, Lopez J, Grappin M, et al. Cross‐sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro–in vivo correlation in HIV‐infected patients. AIDS 1994;. 11: 945–50. [DOI] [PubMed] [Google Scholar]
  • 47. Le Guennec R, Reynes J, Mallie M, Pujol C, Janbon F, Bastide J Fluconazole‐ and itraconazole‐resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilites. J Clin Microbiol 1995;. 11: 2732–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. He X, Tiballi RN, Zarins LT, et al Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;. 11: 2495–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Heald AE, Cox GM, Schell WA, Bartlett Perfet JR Oropharyngeal yeast flora and fluconazole resistance in HIV‐infected patients receiving long‐term continuous vs. intermittent fluconazole therapy. AIDS 1996;. 11: 263–8. [DOI] [PubMed] [Google Scholar]
  • 50. Powderly WG Resistant candidiasis. AIDS Research Human Retrovir 1994;. 11: 925–9. [DOI] [PubMed] [Google Scholar]
  • 51. Gallant JE, Moore RD, Chaisson RE Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994;. 11: 932–44. [DOI] [PubMed] [Google Scholar]
  • 52. MacPhail LA, Hilton JF, Dodd CL, Greenspan D Prophylaxis with nystatin pastilles for HIV‐associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovir 1996;. 11: 470–6. [DOI] [PubMed] [Google Scholar]
  • 53. Just‐Nubling G, Gentshaw G, Meissner K, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV‐positive patients. Eur J Clin Microbiol Infect Dis 1991;. 11: 917–21. [DOI] [PubMed] [Google Scholar]
  • 54. Stevens DA, Greene SI, Lang OS Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome‐related complex: randomized, double‐blind, placebo‐controlled study of 100‐mg oral fluconazole daily. Arch Intern Med 1991;. 11: 2458–64. [PubMed] [Google Scholar]
  • 55. Marriott DJE Fluconazole once a week is secondary prophylaxis against oropharyngeal candidiasis in HIV‐infected patients: A double‐blind placebo‐controlled study. Med J Aust 1993;. 11: 312–6. [DOI] [PubMed] [Google Scholar]
  • 56. Leen CLS, Dunbar EM, Ellis ME, Mandal BK Once‐weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS‐related complex: a double‐blind placebo‐controlled study. J Infect 1990;. 11: 55–60. [DOI] [PubMed] [Google Scholar]
  • 57. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;. 11: 700–5. [DOI] [PubMed] [Google Scholar]
  • 58. Drew WL Cytomegalovirus infections in patients with AIDS. Clin Infect Dis 1992;. 11: 608–15. [DOI] [PubMed] [Google Scholar]
  • 59. Shepp DH, Moses JE, Kaplan MH Seroepidemiology of cytomegalovirus in patients with advanced HIV disease: influence on disease expression and survival. J Acquir Immune Defic Syndr Hum Retrovir 1996;. 11: 460–8. [DOI] [PubMed] [Google Scholar]
  • 60. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;. 11: 1223–7. [DOI] [PubMed] [Google Scholar]
  • 61. Goodgame RW, Genta RM, Estrada R, Demmler G, Buffone G Frequency of positive tests for cytomegalovirus in AIDS patients: endoscopic lesions compared with normal mucosa. Am J Gastroenterol 1993;. 11: 338–43. [PubMed] [Google Scholar]
  • 62. Crumpacker CS Ganciclovir. N Engl J Med 1996;. 11: 721–9. [DOI] [PubMed] [Google Scholar]
  • 63. AIDS Research Group Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995;. 11: 613–21. [DOI] [PubMed] [Google Scholar]
  • 64. Kaiser L, Perrin L, Hirschel B, et al. Foscarnet decreases human immunodeficiency virus RNA. J Infect Dis 1995;. 11: 225–7. [DOI] [PubMed] [Google Scholar]
  • 65. Jacobson MA, O'Donnell JJ, Porteous D, Brodie HR, Feigal D, Mills J Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: Prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988;. 11: 473–86. [PubMed] [Google Scholar]
  • 66. Buhles WC, Mastre BJ, Tinker AJ, et al Ganciclovir treatment of life‐ or sight‐threatening cytomegalovirus infection: Experience in 314 immunocompromised patients. Rev Infect Dis 1988;. 11: 495–506. [DOI] [PubMed] [Google Scholar]
  • 67. Dieterich DT, Chachoua A, Lafleur F, Worrell C Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS. Rev Infect Dis 1988;. 11: 532–7. [DOI] [PubMed] [Google Scholar]
  • 68. Wilcox CM, Straub RF, Schwartz DA Cytomegalovirus esophagitis in AIDS: a prospective study of clinical response to ganciclovir therapy, relapse rate, and long‐term outcome. Am J Med 1995;. 11: 169–76. [DOI] [PubMed] [Google Scholar]
  • 69. Blanshard C Treatment of HIV‐related cytomegalovirus disease of the gastrointestinal tract with foscarnet. J Acquir Immune Defic Syndr 1992; 5(Suppl. 1): S25–8. [PubMed]
  • 70. Wagstaff AJ & Bryson HM Foscarnet. A reapprasial of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994;. 11: 199–226. [DOI] [PubMed] [Google Scholar]
  • 71. Dieterich DT, Kotler DP, Busch DF, et al Ganciclovir treatment of cytomegalovirus colitis in AIDS: A randomized, double‐blind, placebo‐controlled multicenter study. J Infect Dis 1993;. 11: 278–82. [DOI] [PubMed] [Google Scholar]
  • 72. Blanshard C, Benhamou Y, Dohin E, Lernestedt JO, Gazzard BG, Katlama C Treatment of AIDS‐associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995;. 11: 622–8. [DOI] [PubMed] [Google Scholar]
  • 73. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med 1990;. 11: 111–7. [DOI] [PubMed] [Google Scholar]
  • 74. Jacobson MA Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr 1992; 5: S11–7. [PubMed]
  • 75. Polis MA, Spooner KM, Baird BF, et al Anticytomegaloviral activity and safety of cidofovir in patients with human immnodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995;. 11: 882–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Piketty C, Bardin C, Gilquin J, Mahe V, Kazatchkine MD, Chast F Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. J Infect Dis 1996;. 11: 188–90. [DOI] [PubMed] [Google Scholar]
  • 77. Dieterich DT, Poles MA, Dicker M, Tepper R, Lew E Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. Am J Gastroenterol 1993;. 11: 542–8. [PubMed] [Google Scholar]
  • 78. Dieterich DT, Poles MA, Lew EA, et al Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993;. 11: 1184–8. [DOI] [PubMed] [Google Scholar]
  • Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Studies of the Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthal. 1996;. 11: 23–33. [Google Scholar]
  • 80. Spector SA, McKinley GF, Lalezari JP, et al Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996;. 11: 1491–7. [DOI] [PubMed] [Google Scholar]
  • 81. Wilcox CM, Schwartz DA, Clark WS Causes, response to therapy, and long‐term outcome of esophageal ulcer in patients with human immunodeficiency virus infection. Ann Intern Med 1995;. 11: 143–9. [DOI] [PubMed] [Google Scholar]
  • 82. Bagdades EK, Pillay D, Squire SB, O'Neil C, Johnson MA, Griffiths PD Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS 1992;. 11: 1317–20. [DOI] [PubMed] [Google Scholar]
  • 83. Genereau T, Lortholary O, Bouchaud O, et al. Herpes simplex esophagitis in patients with AIDS: Report of 34 cases. Clin Infect Dis 1996;. 11: 926–31. [DOI] [PubMed] [Google Scholar]
  • 84. Laskin OL Clinical pharmacokinetics of acyclovir. Clin Pharmacokin 1983;. 11: 187–201. [DOI] [PubMed] [Google Scholar]
  • 85. Palu G, Gerna G, Bevilacqua F, Marcello A A point mutation in the thymidine kinase gene is responsible for acyclovir‐resistance in herpes simplex virus type 2 sequential isolates. Virus Res 1992;. 11: 133–44. [DOI] [PubMed] [Google Scholar]
  • 86. Laufer DS & Starr SE Resistance to antivirals. Pediatr Clin N Am 1995;. 11: 583–99. [DOI] [PubMed] [Google Scholar]
  • 87. Balfour HH, Jr, Benson C, Braun J, et al. Management of acyclovir‐resistant herpes simplex and varicella‐zoster virus infections. J Acquir Immune Defic Syndr 1994;. 11: 254–60. [PubMed] [Google Scholar]
  • 88. Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet‐resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;. 11: 193–6. [DOI] [PubMed] [Google Scholar]
  • 89. Kitchen VS, Helbert M, Francis ND, et al Epstein–Barr virus associated oesophageal ulcers in AIDS. Gut 1990;. 11: 1223–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Cunningham AL, Grohman GS, Harkness J, et al. Gastrointestinal viral infections in homosexual men who were symptomatic and seropositive for human immunodeficiency virus. J Infect Dis 1988;. 11: 386–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Janoff EN, Orenstein JM, Manischewitz JF, Smith PD Adenovirus colitis in the acquired immunodeficiency syndrome. Gastroenterology 1991;. 11: 976–9. [DOI] [PubMed] [Google Scholar]
  • 92. Khoo SH, Bailey AS, De Jong JC, Mandal BK Adenovirus infections in human immunodeficiency virus‐positive patients: clinical features and molecular epidemiology. J Infect Dis 1995;. 11: 629–37. [DOI] [PubMed] [Google Scholar]
  • 93. Grohmann GS, Glass RI, Pereira HG, et al Enteric viruses and diarrhea in HIV‐infected patients. N Engl J Med 1993;. 11: 14–20. [DOI] [PubMed] [Google Scholar]
  • 94. Schmidt W, Schneider T, Heise W, et al. Stool viruses, coinfections, and diarrhea in HIV‐infected patients. J Acquir Immune Defic Syndr Human Retrovir 1996;. 11: 33–8. [DOI] [PubMed] [Google Scholar]
  • 95. Texidor HS, Godwin TA, Ramirez EA Cryptosporidiosis of the biliary tract in AIDS. Radiology 1991;. 11: 51–6. [DOI] [PubMed] [Google Scholar]
  • 96. Bouche H, Housset C, Dumont JL, et al AIDS‐related cholangitis: diagnostic features and course in 15 patients. J Hepatol 1993;. 11: 34–9. [DOI] [PubMed] [Google Scholar]
  • 97. Connolly GM, Dryden MS, Shanson DC, Gazzard BG Cryptosporidial diarrhea in AIDS and its treatment. Gut 1988;. 11: 593–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98. Goldstein ST, Juranek DD, Ravenholt O, et al. Cryptosporidiosis: An outbreak associated with drinking water despite state‐of‐the‐art water treatment. Ann Intern Med 1996;. 11: 459–68. [DOI] [PubMed] [Google Scholar]
  • 99. Vakil NB, Schwartz SM, Buggy BP, et al Biliary cryptosporidiosis in HIV‐infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Engl J Med 1996;. 11: 19–23. [DOI] [PubMed] [Google Scholar]
  • 100. McGowan I, Hawkins AS, Weller IVD The natural history of cryptosporidia diarrhea in HIV‐infected patients. AIDS 1993;. 11: 349–54. [DOI] [PubMed] [Google Scholar]
  • 101. Flanigan T, Whalen C, Turner J, et al. Cryptosporidium infection and CD4 counts. Ann Intern Med 1992;. 11: 840–2. [DOI] [PubMed] [Google Scholar]
  • 102. Goodgame RW, Kimball K, Ou CN, et al International function and injury in acquired immunodeficiency syndrome‐related cryptosporidiosis. Gastroenterology 1995;. 11: 1075–82. [DOI] [PubMed] [Google Scholar]
  • 103. Armitage K, Flanigan T, Carey J, et al. Treatment of cryptosporidiosis with paromomycin. Arch Intern Med 1992;. 11: 2497–9. [PubMed] [Google Scholar]
  • 104. Greenberg RE, Mir R, Bank S, Siegal FP Resolution of intestinal cryptosporidiosis after treatment of AIDS with AZT. Gastroenterology 1989;. 11: 1327–30. [DOI] [PubMed] [Google Scholar]
  • 105. Simon D, Weiss L, Tanowitz HB, Wittner M Resolution of Cryptosporidium infection in an AIDS patient after improvement of nutritional and immune status with octreotide. Am J Gastroenterol 1991;. 11: 615–8. [PubMed] [Google Scholar]
  • 106. Shield J, Melville C, Novelli V, et al. Bovine colostrum immunoglobulin concentrate for cryptosporidiosis in AIDS. Arch Dis Child 1993;. 11: 451–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Heaton P Bovine colostrum immunoglobulin concentrate for cryptosporidiosis in AIDS. Arch Dis Child 1994;. 11: 356–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Greenberg PD & Cello JP Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovir 1996;. 11: 348–54. [DOI] [PubMed] [Google Scholar]
  • 109. Loeb M, Walach C, Phillips J, et al. Treatment with letrazuril of refractory cryptosporidial diarrhea complicating AIDS. J Acquir Immune Defic Syndr Hum Retrovir 1995;. 11: 48–53. [PubMed] [Google Scholar]
  • 110. Harris M, Deutsch G, MacLean JD, Tsoukas CM A phase I study of letrazuril in AIDS‐related cryptosporidiosis. AIDS 1994;. 11: 1109–13. [DOI] [PubMed] [Google Scholar]
  • 111. Bissuel F, Cotte L, De Montclos M, Rabodonirina M, Trepo C Absence of systemic absorption of oral paromomycin during long‐term, high‐dose treatment for cryptosporidiosis in AIDS. J Infect Dis 1994;. 11: 749–50. [DOI] [PubMed] [Google Scholar]
  • 112. Marshall RJ & Flanigan TP Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line. J Infect Dis 1992;. 11: 772–4. [DOI] [PubMed] [Google Scholar]
  • 113. Cirioni O, Giacometto A, Balducci M, Drenaggi D, Del Prete MS, Scalise G Anticryptosporidial activity of paromomycin. J Infect Dis 1995;. 11: 1169–70. [DOI] [PubMed] [Google Scholar]
  • 114. Clezy K, Gold J, Jones P Paromomycin for the treatment of cryptosporidial diarrhoea in AIDS patients. AIDS 1991;. 11: 1146–7. [PubMed] [Google Scholar]
  • 115. Bissuel F, Cotte L, Rabodonirina M, Rougier P, Piens M‐A, Trepo C Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin Infect Dis 1994;. 11: 447–9. [DOI] [PubMed] [Google Scholar]
  • 116. Scaglia M, Atzori C, Marchetti G, Orso M, Maserati R, Orani A Effectiveness of aminosidine (paromomysin) sulfate in chronic Cryptosporidium diarrhea in AIDS patients: An open, uncontrolled, prospective clinical trial. J Infect Dis 1994;. 11: 1349–50. [DOI] [PubMed] [Google Scholar]
  • 117. White AC, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW Paromomycin for cryptosporidiosis in AIDS: A prospective, double‐blind trial. J Infect Dis 1994;. 11: 419–24. [DOI] [PubMed] [Google Scholar]
  • 118. Molina JM, Sarfati C, Beauvais B, et al. Intestinal microsporidiosis in human immunodeficiency virus‐infected patients with chronic unexplained diarrhea: Prevalence and clinical and biologic features. J Infect Dis 1993;. 11: 217–21. [DOI] [PubMed] [Google Scholar]
  • 119. Kotler DP & Orenstein JM Prevalence of intestinal microsporidiosis in HIV‐infected patients referred for gastroenterological evaluation. Am J Gastroenterol 1994;. 11: 1998–2002. [PubMed] [Google Scholar]
  • 120. Pol S, Romana CA, Richard S, et al. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N Engl J Med 1993;. 11: 95–9. [DOI] [PubMed] [Google Scholar]
  • 121. Weber R, Bryan RT, Schwartz DA, Owen RL Human microsporidial infections. Clin Microbiol Rev 1994;. 11: 426–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122. Goodgame RW Understanding intestinal spore‐forming protozoa: Cryptosporidia, microsporidia, isospora, and cyclospora. Ann Intern Med 1996;. 11: 429–41. [DOI] [PubMed] [Google Scholar]
  • 123. Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994;. 11: 819–25. [DOI] [PubMed] [Google Scholar]
  • 124. Kotler DP, Giang TT, Garro ML, Orenstein JM Light microscopic diagnosis of microsporidiosis in patients with AIDS. Am J Gastroenterol 1994;. 11: 540–4. [PubMed] [Google Scholar]
  • 125. Weber R, Bryan RT, Owen RL, Wilcox CM, Gorelkin L, Visvesvara GS Improved light‐microscopical detection of microsporidia spores in stool and duodenal aspirates. N Engl J Med 1992;. 11: 161–6. [DOI] [PubMed] [Google Scholar]
  • 126. Eeftinck Schattenkerk JKM, Van Gool T, Van Ketel RJ, et al Clinical significance of small‐intestinal microsporidiosis in HIV‐1‐infected individuals. Lancet 1991;. 11: 895–8. [DOI] [PubMed] [Google Scholar]
  • 127. Dore GJ, Marriott DJ, Hing MC, Harkness JL, Field AS Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: Response to therapy with albendazole. Clin Infect Dis 1995;. 11: 70–6. [DOI] [PubMed] [Google Scholar]
  • 128. Anwar‐Bruni DM, Hogan SE, Schwartz DA, Wilcox CM, Bryan RT, Lennox JL Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV‐1 infected patients. AIDS 1996;. 11: 619–24. [DOI] [PubMed] [Google Scholar]
  • 129. Dieterich DT, Lew EA, Kotler DP, Poles MA, Orenstein JM Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994;. 11: 178–83. [DOI] [PubMed] [Google Scholar]
  • 130. Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS. Clinical features and response to albendazole therapy. J Infect Dis 1995;. 11: 245–9. [DOI] [PubMed] [Google Scholar]
  • 131. Soave R Cyclospora: An overview. Clin Infect Dis 1996;. 11: 429–37. [DOI] [PubMed] [Google Scholar]
  • 132. Pape JW, Verdier R‐I, Boncy M, Boncy J, Johnson WD Cyclospora infection in adults infected with HIV: Clinical manifestations, treatment, and prophylaxis. Ann Intern Med 1994;. 11: 654–7. [DOI] [PubMed] [Google Scholar]
  • 133. Farthing MJG Giardiasis. Gastroenterol Clin North Am 1996;. 11: 493–515. [DOI] [PubMed] [Google Scholar]
  • 134. Jessurun J, Barron‐Rodriquez LP, Fernandez‐Tinoco G, Hernandez‐Avila M The prevalence of invasive amebiasis is not increased in patients with AIDS. AIDS 1992;. 11: 307–9. [DOI] [PubMed] [Google Scholar]
  • 135. Allason‐Jones E, Mindel A, Sargeaunt P, Williams P Entamoeba histolytica as a commensal intestinal parasite in homosexual men. N Engl J Med 1986;. 11: 353–6. [DOI] [PubMed] [Google Scholar]
  • 136. Peters CS, Sable R, Janda WM, Chittom AL, Kocka FE Prevalence of enteric parasites in homosexual patients attending an outpatient clinic. J Clin Microbiol 1986;. 11: 684–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137. Laughon BE, Druckman DA, Vernon A, et al. Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology 1988;. 11: 984–93. [DOI] [PubMed] [Google Scholar]
  • 138. Cotte L, Rabodonirina M, Piens MA, Perreard M, Mojon M, Trepo C Prevalence of intestinal protozoans in French patients infected with HIV. J Acquir Immune Defic Syndr 1993;. 11: 1024–9. [PubMed] [Google Scholar]
  • 139. Burchard GD, Hufert FT, Mirelman D Characterisation of 20 Entamoeba histolytica strains isolated from patients with HIV infection. Infection 1991;. 11: 44–9. [DOI] [PubMed] [Google Scholar]
  • 140. Havlik JA, Horsburgh CR, Metchock B, Williams PP, Fann SA, Thompson SE Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992;. 11: 577–80. [DOI] [PubMed] [Google Scholar]
  • 141. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA Incidence of Mycobacterium avium‐intracellulare complex bacteremia in human immunodeficiency virus‐positive patients. J Infect Dis 1992;. 11: 1082–5. [DOI] [PubMed] [Google Scholar]
  • 142. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T Incidence and natural history of Mycobacterium avium‐complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Resp Dis 1992;. 11: 285–9. [DOI] [PubMed] [Google Scholar]
  • 143. Moore RD & Chaisson RE Natural history of opportunistic disease in an HIV‐infected urban clinical cohort. Ann Intern Med 1996;. 11: 633–42. [DOI] [PubMed] [Google Scholar]
  • 144. Lanjewar DN, Anand BS, Genta R, et al. Major differences in the spectrum of gastrointestinal infections associated with AIDS in India vs. the west: An autopsy study. Clin Infect Dis 1996;. 11: 482–5. [DOI] [PubMed] [Google Scholar]
  • 145. Gray JR & Rabeneck L Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol 1989;. 11: 1521–4. [PubMed] [Google Scholar]
  • 146. Greene JB, Sidhu GS, Lewin S, et al. Mycobacterium avium‐intracellulare: a cause of disseminated life‐threatening infection in homosexuals and drug abusers. Ann Intern Med 1982;. 11: 539–46. [DOI] [PubMed] [Google Scholar]
  • 147. Torriani F, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis 1994;. 11: 1601–5. [DOI] [PubMed] [Google Scholar]
  • 148. Farhi DC, Mason UG, Horsburgh CR Pathologic findings in disseminated Mycobacterium avium‐intracellulare infection. Am J Clin Pathol 1986;. 11: 67–72. [DOI] [PubMed] [Google Scholar]
  • 149. Benson C Disseminated Mycobacterium avium‐intracellulare complex in patients with AIDS. AIDS Res Hum Retroviruses 1994;. 11: 913–6. [DOI] [PubMed] [Google Scholar]
  • 150. Havlik JA, Metchock B, Thompson SE, Barrett K, Rimland D, Horsburgh CR A prospective evaluation of Mycobacterium avium complex colonization of the respiratory and gastrointestinal tracts of persons with human immunodeficiency virus infection. J Infect Dis 1993;. 11: 1045–8. [DOI] [PubMed] [Google Scholar]
  • 151. Chin DP, Hopewell PC, Yajko DM, et al Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994;. 11: 289–95. [DOI] [PubMed] [Google Scholar]
  • 152. Kemper CA, Meng T‐C, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four‐drug oral regimen: Rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992;. 11: 466–72. [DOI] [PubMed] [Google Scholar]
  • 153. Benson C Disseminated Mycobacterium avium complex disease in patients with AIDS. AIDS Res Hum Retroviruses 1994;. 11: 913–6. [DOI] [PubMed] [Google Scholar]
  • 154. Chaisson RE, Benson CA, Dube MP, et al Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomized, double‐blind, dose‐ranging study in patients with AIDS. Ann Intern Med 1994;. 11: 905–11. [DOI] [PubMed] [Google Scholar]
  • 155. Shafran SD, Singer J, Zarowny DP, et al A comparision of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithroymcin vs. rifampin, ethambutol, clofazimine, and ciprofloxacin. N Eng J Med 1996;. 11: 377–83. [DOI] [PubMed] [Google Scholar]
  • 156. Marshall JB Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroentol 1993;. 11: 989–99. [PubMed] [Google Scholar]
  • 157. Nightengale SD, Cameron DW, Gordin FM, et al Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;. 11: 828–33. [DOI] [PubMed] [Google Scholar]
  • 158. Masur H Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;. 11: 898–904. [DOI] [PubMed] [Google Scholar]
  • 159. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;. 11: 384–91. [DOI] [PubMed] [Google Scholar]
  • 160. Havlir DV, Dube MP, Sattler FR, et al Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;. 11: 392–8. [DOI] [PubMed] [Google Scholar]
  • 161. Smith PD, Lane HC, Gill VJ, et al Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS): etiology and response to therapy. Ann Intern Med 1988;. 11: 328–33. [DOI] [PubMed] [Google Scholar]
  • 162. Molina JM, Casin I, Hausfater P, et al. Campylobacter infections in HIV‐infected patients: clinical and bacteriological features. AIDS 1995;. 11: 881–5. [DOI] [PubMed] [Google Scholar]
  • 163. Smith PD, Macher AM, Bookman MA, et al Salmonella typhimurium enteritis and bacteremia in the acquired immunodeficiency syndrome. Ann Intern Med 1985;. 11: 207–9. [DOI] [PubMed] [Google Scholar]
  • 164. Rene E, Marche C, Regnier B, et al. Intestinal infections in patients with acquired immunodeficiency syndrome: A prospective study in 132 patients. Dig Dis Sci 1989;. 11: 773–80. [DOI] [PubMed] [Google Scholar]
  • 165. Nelson MR, Shanson DC, Hawkins D, Gazzard BG Shigella in HIV infection. AIDS 1991;. 11: 1031–2. [PubMed] [Google Scholar]
  • 166. Kotler DP, Giang TT, Thiim M, Nataro JP, Sordillo EM, Orenstein JM Chronic bacterial enteropathy in patients with AIDS. J Infect Dis 1995;. 11: 552–8. [DOI] [PubMed] [Google Scholar]
  • 167. Hutin Y, Molina JM, Casin I, et al. Risk factors for Clostridium difficile‐associated diarrhoea in HIV‐infected patients. AIDS 1993;. 11: 1441–7. [DOI] [PubMed] [Google Scholar]
  • 168. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med 1995;. 11: 835–40. [DOI] [PubMed] [Google Scholar]
  • 169. Lu SS, Schwartz JM, Simon DM, Brandt LJ Clostridium difficile‐associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol 1994;. 11: 1226–9. [PubMed] [Google Scholar]
  • 170. Rabeneck L, Popovic M, Gartner S, et al. Acute HIV infection presenting with painful swallowing and esophageal ulcers. J Am Med Assoc 1990;. 11: 2318–22. [PubMed] [Google Scholar]
  • 171. Jalfon IM, Sitton JE, Hammer RA, Agrawal NM, Ertan A, Mahatma M HIV‐1 gp41 antigen demonstration in esophageal ulcers with acquired immunodeficiency syndrome. J Clin Gastroenterol 1991;. 11: 664–8. [DOI] [PubMed] [Google Scholar]
  • 172. Kotler DP, Reka S, Orenstein JM, Fox CH Chronic idiopathic esophageal ulceration in the acquired immunodeficiency syndrome. J Clin Gastroenterol 1992;. 11: 284–90. [DOI] [PubMed] [Google Scholar]
  • 173. Smith PD, Eisner MS, Manischewitz JF, Gill VJ, Masur H, Fox CF Esophageal disease in AIDS is associated with pathologic processes rather than mucosal human immunodeficiency virus type 1. J Infect Dis 1993;. 11: 547–52. [DOI] [PubMed] [Google Scholar]
  • 174. Wilcox CM, Zaki SR, Coffield LM, Greer PW, Schwartz DA Evaluation of idiopathic esophageal ulcer for human immunodeficiency virus. Mod Pathol 1995;. 11: 568–72. [PubMed] [Google Scholar]
  • 175. Wilcox CM, Straub RA, Schwartz DA Prospective endoscopic characterization of cytomegalovirus esophagitis in patients with AIDS. Gastrointest Endosc 1994;. 11: 481–4. [DOI] [PubMed] [Google Scholar]
  • 176. Wilcox CM & Schwartz DA Comparison of two corticosteroid regimens for the treatment of idiopathic esophageal ulcerations associated with HIV infection. Am J Gastroenterol 1994;. 11: 2163–7. [PubMed] [Google Scholar]
  • 177. Nelson MR, Erskine D, Hawkins DA, Gazzard BG Treatment with corticosteroids—a risk factor for the development of clinical cytomegalovirus disease in AIDS. AIDS 1993;. 11: 375–8. [DOI] [PubMed] [Google Scholar]
  • 178. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Inf Dis 1995;. 11: 250–4. [DOI] [PubMed] [Google Scholar]
  • 179. Alexander LN & Wilcox CM A prospective trial of thalidomide for the treatment of HIV‐associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 1997; 13: 3014. [DOI] [PubMed]
  • 180. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J Exp Med 1991;. 11: 699–703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181. Gunzler V Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Safety 1992;. 11: 116–34. [DOI] [PubMed] [Google Scholar]
  • 182. Shiller LR Review article: antidiarrhoel pharmacology and therapeutics. Aliment Pharmacol Ther 1995;. 11: 87–106. [PubMed] [Google Scholar]
  • 183. Cello JP, Grendell JH, Basuk P, et al. Effect of octreotide on refractory AIDS‐associated diarrhea. A prospective multicenter clinical trial. Ann Intern Med 1991;. 11: 705–10. [DOI] [PubMed] [Google Scholar]
  • 184. Compean DG, Jimenez JR, De La Garza FG, et al Octreotide therapy of large‐volume refractory AIDS‐associated diarrhea: a randomized controlled trial. AIDS 1994;. 11: 1563–7. [DOI] [PubMed] [Google Scholar]
  • 185. Montaner JSG, Harris AG and, The Octreotide International Multicentre AIDS–Diarrhea Study Group Octreotide therapy in AIDS‐related, refractory diarrhea: results of a multicentre Canadian–European study. AIDS 1995;. 11: 209–10(Letter). [PubMed] [Google Scholar]
  • 186. Simon DM, Cello JP, Valenzuela J, et al. Multicenter trial of octreotide in patients with refractory aquired immunodeficiency syndrome‐associated diarrhea. Gastroenterology 1995;. 11: 1753–60. [DOI] [PubMed] [Google Scholar]

Articles from Alimentary Pharmacology & Therapeutics are provided here courtesy of Wiley

RESOURCES